Morganton

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3, randomized, placebo-controlled study. This trial focuses on patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study aims to assess how AZD0780 compares to placebo in reducing the risk of major adverse cardiovascular events, also known as MACE-PLUS, over the course of the trial. Participants are randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study continues until a primary analysis censoring date, which may be up to approximately 54 months from randomization. After this, a study closure visit will be conducted as the final visit for each participant. During the study, participants will be regularly monitored for cardiovascular events including heart attacks, strokes, urgent coronary revascularizations, and other related outcomes. Researchers will track the time to first occurrence of these events as the primary outcome. Safety and other secondary outcomes like all-cause mortality will also be assessed. The total participation time can last up to about 54 months, with ongoing evaluations throughout this period.

Researchers are studying maridebart cafraglutide to evaluate its effect on reducing cardiovascular problems and death in people with atherosclerotic cardiovascular disease who are also overweight or obese. This Phase 3 trial compares maridebart cafraglutide to a placebo, both given alongside standard care, to see if maridebart cafraglutide works better in lowering heart-related risks. Participants will receive either maridebart cafraglutide or a placebo, both administered by subcutaneous injection. The study lasts for up to approximately 35 months, during which researchers monitor several heart and health outcomes. These include heart attacks, strokes, death rates, hospitalizations, blood pressure, body measurements, blood sugar control, cholesterol levels, kidney function, and inflammatory markers. During the trial, participants will have regular assessments including physical exams, blood tests, and monitoring of heart events. Researchers track the time to first major heart-related events and changes in health markers over the study period. Safety is also monitored by recording any adverse events. The total participation time can last nearly three years, allowing careful observation of the effects of the study drug compared to placebo.

Researchers are evaluating the safety and effectiveness of the dNerva Lung Denervation System as a one-time treatment to improve breathing in adults with Chronic Obstructive Pulmonary Disease COPD. The study compares adding this new device treatment to standard COPD medical care versus standard care alone in patients who have high residual lung volume and low emphysema. The goal is to see if lung function improves and to confirm the safety of the lung denervation procedure. Participants are randomly assigned to one of two groups one group receives the Targeted Lung Denervation TLD therapy using the dNerva system along with their usual COPD medications, and the other group continues with their standard medical care without additional intervention. The TLD therapy is a minimally invasive bronchoscopic treatment done once. Those in the control group who complete one year of follow-up may opt to receive the TLD treatment afterward and will be monitored for an additional year. During the study, participants will undergo various tests and assessments including lung function measurements like FEV1 at 6 and 12 months, lung volume changes, breathing difficulty scores, quality of life questionnaires, and tracking of COPD flare-ups over a year. Safety will be closely monitored throughout. The study lasts at least one year for primary follow-up, with some participants followed longer if they crossover to receive the treatment after one year.